Quest Diagnostics Study Reveals High Co-Infection Rates in Lyme Disease Patients
Event summary
- Quest Diagnostics study of 193,260 patients found 29.5% with Lyme disease antibodies also had antibodies for other tick-borne pathogens.
- Northeastern U.S. patients were twice as likely to have co-detected non-Lyme disease pathogens compared to other regions.
- Babesia microti was the most commonly co-detected pathogen among Lyme disease patients, especially in the Northeast.
- More than 40% of diagnostic panel testing occurred during summer months, reflecting seasonal tick activity.
The big picture
The study highlights the growing complexity of tick-borne disease diagnostics, with co-infections requiring distinct treatment protocols. As climate change and expanding tick populations drive higher infection rates, Quest Diagnostics is positioned to capitalize on the need for more comprehensive diagnostic solutions. The findings underscore the importance of regional health data in tailoring diagnostic and treatment strategies, particularly in Lyme disease-endemic areas.
What we're watching
- Diagnostic Testing Evolution
- How Quest Diagnostics will leverage these findings to expand its comprehensive testing offerings for tick-borne diseases.
- Regional Health Disparities
- Whether the Northeast's higher co-infection rates will drive targeted public health interventions and increased diagnostic demand.
- Seasonal Testing Patterns
- The pace at which summer and fall testing volumes will influence Quest Diagnostics' operational planning and resource allocation.